CJ BioscienceCJ 바이오사이언스
311690 · KOSDAQ · ₩311690 · CJ 바이오사이언스
- Market cap
- ₩48B
- Enterprise value
- ₩16B
- P/E
- —
- P/B
- 1.2×
- Dividend yield
- 0.0%
- ROE
- −53.5%
- Net margin
- −607.2%
Trailing 12 months from filed financial statements, as of H1 2026. Dividend yield: the 2025 dividend per share from the annual report ÷ today's price.
52-week range−63.8% from the high
₩3,060Today: ₩3,500 – ₩3,980₩10,200
Returns
- 1W0.0%
- 1M−1.1%
- 3M+15.9%
- 6M−52.6%
- YTD−60.4%
- 1Y−60.5%
- Volume today
- 5,731
- 0.9× the 20-day average
- Traded today
- ₩21M
- Listed shares
- 13,065,462
- EPS (12 months)
- −₩1,709
- Earnings yield −46.3%
Upcoming dates
Full calendar →🎁 Gift this stock
Send a friend ₩100,000 of paper money in this stock. They get it when they join.
Signals
Quiet- BuzzQuietBuzz 42 of 100 (50 is a normal day for this stock).
- MomentumFlat-1.3% over the last month; the price is below its 20-day average.
Signals describe activity, not recommendations. Not financial advice.
CJ Bioscience stock overview
CJ Bioscience (CJ 바이오사이언스, KRX: 311690) is listed on KOSDAQ, in the Biotech & Pharma sector. The company develops microbiome-based drugs, with its lead candidate CJRB-101 in clinical trials for lung and head-and-neck cancers in combination with Keytruda in the US and Korea. Its shares closed at ₩3,690 on Oct 29, 2026, up 1.10% on the day, giving it a market value of ₩48B.
Key facts
- Market cap
- ₩48B
- Sector
- Biotech & Pharma
- Latest price change
- +1.10%
- As of
- Oct 29, 2026
- Main business
- The company develops microbiome-based drugs, with its lead candidate CJRB-101 in clinical trials for lung and head-and-neck cancers in combination with Keytruda in the US and Korea.
Quick answers about CJ Bioscience
- What does CJ Bioscience do?
- The company develops microbiome-based drugs, with its lead candidate CJRB-101 in clinical trials for lung and head-and-neck cancers in combination with Keytruda in the US and Korea. It also provides microbiome genomics bioinformatics platforms and NGS/BI solutions, built on its EzBioCloud database, to universities, government agencies, companies, and medical institutions. Its health and wellness business offers gut microbiome analysis services, including GUT INSIDE for medical institutions and SMILE GUT for consumers, and it serves customers in Korea and, for its solutions, the United States and Asia.
- What is the market cap of CJ Bioscience?
- The market capitalisation of CJ Bioscience was ₩48B at the close on Oct 29, 2026.
- Who are the largest shareholders of CJ Bioscience?
- According to the latest official filings, the largest reported holders are CJ CheilJedang (65.49%, as of Dec 19, 2024).
- When is the next earnings report from CJ Bioscience?
- Korean companies rarely announce results dates in advance. Based on when CJ Bioscience filed the same report in past years, its next 3q results is expected around Nov 14, 2026.
Company profile
The company develops microbiome-based drugs, with its lead candidate CJRB-101 in clinical trials for lung and head-and-neck cancers in combination with Keytruda in the US and Korea. It also provides microbiome genomics bioinformatics platforms and NGS/BI solutions, built on its EzBioCloud database, to universities, government agencies, companies, and medical institutions. Its health and wellness business offers gut microbiome analysis services, including GUT INSIDE for medical institutions and SMILE GUT for consumers, and it serves customers in Korea and, for its solutions, the United States and Asia.
Written by AI from the company's latest annual report.
- Korean name
- CJ 바이오사이언스
- Sector
- Biotech & Pharma
- Business group
- CJ
- CEO
- 윤상배
- Founded
- Nov 2009
- Listed
- Dec 2019
- Listed shares
- 13,065,462
- Fiscal year ends
- Month 12
- Website
- www.cjbioscience.com
Similar companies
- Samsung Biologics207940 · ₩63T₩1,366,000−0.44%
- Celltrion068270 · ₩44T₩189,300−0.26%
- Alteogen196170 · ₩15T₩220,000−1.35%
- SK biopharmaceuticals326030 · ₩6.1T₩77,800+3.46%
- Yuhan000100 · ₩5.5T₩74,700−3.36%
- HLB028300 · ₩5.3T₩39,700−2.34%
- Hanmi Pharm128940 · ₩5T₩388,500+5.14%
- SAM Chun Dang Pharm000250 · ₩4.4T₩188,600−0.74%
Recent filings
See all- Disclosure on Large Business Group Status [Quarterly Disclosure (For Individual Company)]Aug 28, 2026
- Half-year report (Jun 2026)Aug 14, 2026
- Matters Concerning Payment Amounts by Payment Method and Payment Period, and Dispute Mediation BodiesAug 14, 2026
- Disclosure of Large Business Group Status [Annual Disclosure and Q1 Use (Individual Companies)]Jun 1, 2026
- Quarterly report (Mar 2026)May 15, 2026
Titles in Korean until English translations are added.
Also known as: CJ Bioscience / CJ 바이오사이언스 / 311690 / KRX:311690
Source: KRX statistical information